Summary
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2016’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease
- The report reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dementia Associated With Alzheimer's Disease therapeutics and enlists all their major and minor projects
- The report assesses Dementia Associated With Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dementia Associated With Alzheimer's Disease
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dementia Associated With Alzheimer's Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adamas Pharmaceuticals, Inc.
AgeneBio Inc.
Amarantus Bioscience Holdings, Inc.
Boehringer Ingelheim GmbH
Chase Pharmaceuticals Corporation
Eisai Co., Ltd.
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
MediPost Co., Ltd.
Neurodyn Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Dementia Associated With Alzheimer's Disease Overview 8
Therapeutics Development 9
Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 9
Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 10
Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 11
Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 12
Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Dementia Associated With Alzheimer's Disease - Products under Development by Companies 17
Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 18
Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 19
Adamas Pharmaceuticals, Inc. 19
AgeneBio Inc. 20
Amarantus Bioscience Holdings, Inc. 21
Boehringer Ingelheim GmbH 22
Chase Pharmaceuticals Corporation 23
Eisai Co., Ltd. 24
FORUM Pharmaceuticals Inc. 25
H. Lundbeck A/S 26
MediPost Co., Ltd. 27
Neurodyn Inc. 28
Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BI-409306 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CPC-201 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
E-2609 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
eltoprazine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
encenicline hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Gln-1062 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
levetiracetam - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LUAF-20513 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Neurostem - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
salicylamine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
TAK-070 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Dementia Associated With Alzheimer's Disease - Recent Pipeline Updates 57
Dementia Associated With Alzheimer's Disease - Dormant Projects 67
Dementia Associated With Alzheimer's Disease - Discontinued Products 68
Dementia Associated With Alzheimer's Disease - Product Development Milestones 69
Featured News & Press Releases 69
Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression 69
Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia 71
Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer’s Dementia 72
Jan 28, 2015: AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer’s Dementia 73
May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories 74
May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77
List of Tables
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2016 9
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Comparative Analysis by Unknown Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 19
Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H1 2016 20
Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 21
Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2016 22
Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2016 23
Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2016 24
Dementia Associated With Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H1 2016 25
Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H1 2016 26
Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H1 2016 27
Dementia Associated With Alzheimer's Disease - Pipeline by Neurodyn Inc., H1 2016 28
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Stage and Target, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 33
Number of Products by Stage and Route of Administration, H1 2016 35
Number of Products by Stage and Molecule Type, H1 2016 37
Dementia Associated With Alzheimer's Disease Therapeutics - Recent Pipeline Updates, H1 2016 57
Dementia Associated With Alzheimer's Disease - Dormant Projects, H1 2016 67
Dementia Associated With Alzheimer's Disease - Discontinued Products, H1 2016 68
List of Figures
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2016 9
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 14
Assessment by Monotherapy Products, H1 2016 29
Number of Products by Top 10 Targets, H1 2016 30
Number of Products by Stage and Top 10 Targets, H1 2016 30
Number of Products by Mechanism of Actions, H1 2016 32
Number of Products by Stage and Mechanism of Actions, H1 2016 32
Number of Products by Routes of Administration, H1 2016 34
Number of Products by Stage and Routes of Administration, H1 2016 34
Number of Products by Molecule Types, H1 2016 36
Number of Products by Stage and Molecule Types, H1 2016 36
